Superworth

Clene revenue CLNN

Sales by quarter and over the last twelve months, from 2020.

Last 12 months, to Jun 30, 2026
$197K
Latest quarter, Q2 FY26
$90K
+233% on a year earlier
Fiscal year 2025
$200K
−42% on the year before

Clene's revenue was $197K over the twelve months to Jun 30, 2026, down 31% on a year earlier.

In its latest quarter, Q2 FY26, it was $90K, up 233% on the same quarter a year before.

Over the five fiscal years to FY2025 it shrank 1% a year on average.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$200K−42%
FY2024$342K−48%
FY2023$654K+38%
FY2022$473K−35%
FY2021$723K+251%
FY2020$206Kn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$90K+233%$197K
Q1 FY26$15K−81%$134K
Q4 FY25$77K−15%$200K
Q3 FY25$15K−83%$214K
Q2 FY25$27K−70%$286K
Q1 FY25$81K+11%$350K
Q4 FY24$91K−46%$342K
Q3 FY24$87K−19%$421K
Q2 FY24$91K−66%$442K
Q1 FY24$73K−32%$620K
Q4 FY23$170K−27%$654K
Q3 FY23$108K−38%$718K

Against its peers

Companies in Drug Manufacturers - General nearest Clene's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
CLNNClene$197K−31% a year
ATNMActinium Pharmaceuticalsn/m
SPROSpero Therapeutics$47M−3% a year
LFVNLifevantage$182.6M−20% a year
NATRNatures Sunshine Products$492M+7% a year
ARVNArvinas$316.7M−15% a year
Peer median$249.6M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Clene

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.